

Top ten vaccine industry events – 2015

LONDON, UK----12st December 2014----ExpertREACT. Once again, the vaccine industry experiences another eventful year. While some news was expected, the most surprising must be that the industry is now racing to develop an Ebola vaccine.

VacZine Analytics lists what we see as the year's top ten events.

1. The second *meningococcal* serogroup b vaccine: **TRUMENBA** (Pfizer) approved in the US (10 - 25 yrs)
2. First available Phase III efficacy data from Sanofi's **dengue vaccine** in both Asia and Latin America
3. Acquisition of **Novartis Vaccines** business (excluding influenza) by **GlaxoSmithKline Plc**
4. Acquisition of Novartis Vaccines influenza business by **BioCSL**
5. The largest **Ebola virus** epidemic in history and subsequent Phase I data of fast tracked ebola vaccine candidates
6. Clinical evidence that **PCV-13 pneumococcal** vaccine (Pfizer) can prevent first episodes of vaccine type community acquired pneumonia and invasive *pneumococcal* disease (IPD) in person >65 yrs (**CAPiTA**)
7. Pfizer acquires **Baxter's** portfolio of vaccines
8. Publication of evidence that **Sanofi's Fluzone HD** vaccine can provide additional protection against influenza in >65 yrs
9. US FDA Fast track designation of Pfizer's ***Clostridium difficile*** vaccine (Phase II)
10. India's provision of the **pentavalent** pediatric combination vaccine available for all infants

*****NOT FOR UNAUTHORIZED COPYING AND DISTRIBUTION*****

***Top 5 companies:** GSK Biologicals, Sanofi Pasteur, Merck & Co, Pfizer (Wyeth) and Novartis Vaccines and Diagnostics

© 2014 VacZine Analytics. All rights reserved.

